Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven I&g Vct5 Regulatory News (MIG5)

Share Price Information for Maven I&g Vct5 (MIG5)

Share Price is delayed by 15 minutes
Get Live Data
28.80    0.00 (0.00%)
Bid:
27.80
Ask:
29.80
Spread: 2.00 (7.194%)
Market Cap: £76.28m
MIG5 Live PriceLast checked at - London Stock Exchange

Intraday Maven I&g Vct5 Share Chart

Issue of Equity

19 Feb 2025 10:12

RNS Number : 7088X
Maven Income and Growth VCT 5 PLC
19 February 2025
Β 

Maven Income and Growth VCT 5 PLC

(the Company)

Β 

Issue of Equity

Β 

On 27 September 2024, the Company launched an offer for subscription for new ordinary shares of 10p each (Ordinary Shares) to raise up to Β£5 million, with an over-allotment facility for up to a further Β£5 million (the Offer).

Β 

Pursuant to the Offer, a total of Β£3,942,714 of valid applications were received in the period from 12.00 noon on 13 December 2024 up to and including 9.00am on 14 February 2025 in respect of the 2024/2025 tax year. As a result, the Company has issued and allotted 11,989,923 new Ordinary Shares on 19 February 2025. In accordance with the allotment formula set out in the prospectus for the Offer, the offer prices at which the shares were issued were in the range of 32.39p to 33.25p per Ordinary Share and, as a result, the number of Ordinary Shares now in issue is 226,324,606. Therefore, the total number of voting rights in the Company is 226,324,606 and this may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.

Β 

In respect of this allotment, an application will be made by the Company to the FCA and to the London Stock Exchange for the new Ordinary Shares to be admitted to the Official List and to trading on the London Stock Exchange's main market for listed securities. It is expected that the admission of the new Ordinary Shares will become effective, and dealings will commence, on or around 21 February 2025.

Β 

This is the second allotment in respect of the 2024/2025 tax year and the Board of the Company intends that further allotments in respect of applications for the 2024/2025 tax year will take place on, or before, 31 March 2025 and on, or before, 4 April 2025. It is also intended that an allotment in respect of applications for the 2025/2026 tax year will take place on, or before, 2 May 2025. The Company's Offer has, to date, received applications totalling Β£6,432,717 for both tax years.

Β 

For further information, please contact:

Β 

Maven Capital Partners UK LLP

Telephone: 0141 306 7400

E-mail: enquiries@mavencp.com

Β 

Maven Capital Partners UK LLP

Secretary

Β 

19 February 2025

Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
IOEPKCBDKBKDDBD
Date   Source Headline
20th May 202610:20 amRNSAdmission of Further Securities to Trading
15th May 202610:10 amRNSIssue of Equity - Dividend Investment Scheme
12th May 20263:39 pmRNSUnaudited NAV - Dividend Investment Scheme
8th May 20264:10 pmRNSTransaction in Own Shares
28th Apr 20263:55 pmRNSResult of AGM
28th Apr 20261:35 pmRNSResult of AGM
20th Apr 202612:23 pmRNSPublication of a Supplementary Prospectus
15th Apr 202611:30 amRNSAdmission of Further Securities to Trading
14th Apr 202611:11 amRNSIssue of Equity
8th Apr 20269:35 amRNSAdmission of Further Securities to Trading
27th Mar 20265:07 pmRNSOffer for Subscription - Fully Subscribed
25th Mar 202610:59 amRNSAdmission of Further Securities to Trading
25th Mar 20267:00 amRNSAnnual Financial Report
24th Mar 202612:13 pmRNSIssue of Equity
17th Mar 20264:36 pmRNSUnaudited Net Asset Value
3rd Mar 20264:31 pmRNSTransaction in Own Shares - correction
27th Feb 20265:04 pmRNSTransaction in Own Shares
26th Feb 20264:53 pmRNSTransaction in Own Shares
26th Feb 20269:15 amRNSDividend Declaration
18th Feb 20265:01 pmRNSAdmission of Further Securities to Trading
17th Feb 202611:11 amRNSDirector/PDMR Shareholding
17th Feb 202610:58 amRNSIssue of Equity
4th Feb 20267:00 amRNSStatement re Offer for Subscription
21st Jan 202611:13 amRNSAdmission of Further Securities to Trading
16th Jan 20269:47 amRNSIssue of Equity
14th Jan 20262:44 pmRNSUnaudited NAV - Dividend Investment Scheme
16th Dec 202511:15 amRNSDirector/PDMR Shareholding
16th Dec 202510:30 amRNSIssue of Equity
4th Dec 202510:35 amRNSUnaudited NAV and Second Interim Dividend
13th Nov 20253:45 pmRNSResult of General Meeting
7th Oct 20254:15 pmRNSTransaction in Own Shares
2nd Oct 20254:42 pmRNSPublication of a Prospectus
15th Sep 20251:11 pmRNSNet Asset Value(s)
29th Aug 20257:00 amRNSIssue of Equity
20th Aug 20252:17 pmRNSStatement re Dividend Investment Scheme
17th Jul 20253:21 pmRNSHalf-year Report
16th Jul 20255:33 pmRNSTransaction in Own Shares
16th Jul 20257:08 amRNSStatement re Offer for Subscription
10th Jul 20254:50 pmRNSStatement re Unaudited NAV and Interim Dividend
14th May 20254:46 pmRNSTransaction in Own Shares
9th May 20259:59 amRNSIssue of Equity
6th May 202511:55 amRNSIssue of Equity
2nd May 20251:27 pmRNSUnaudited NAV - Dividend Investment Scheme
29th Apr 20253:20 pmRNSResult of AGM
17th Apr 202512:56 pmRNSPublication of Suppl.Prospcts
15th Apr 20259:32 amRNSDirector/PDMR Shareholding
4th Apr 20256:22 pmRNSIssue of Equity
1st Apr 202512:59 pmRNSStatement re Offers for Subscription - Closed
27th Mar 20251:14 pmRNSDirector/PDMR Shareholding
27th Mar 20251:09 pmRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.